Page last updated: 2024-08-21

cyclopentane and Hematologic Malignancies

cyclopentane has been researched along with Hematologic Malignancies in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Faessel, HM; Faller, DV; Mould, DR; Sedarati, F; Venkatakrishnan, K; Zhou, X1
Akimoto, M; Honma, Y; Ishii, Y; Ishikura, H; Kiyota, H; Tsumura, H1

Other Studies

2 other study(ies) available for cyclopentane and Hematologic Malignancies

ArticleYear
Population pharmacokinetics of pevonedistat alone or in combination with standard of care in patients with solid tumours or haematological malignancies.
    British journal of clinical pharmacology, 2019, Volume: 85, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biological Variation, Population; Clinical Trials as Topic; Cyclopentanes; Drug Interactions; Drugs, Investigational; Female; Hematologic Neoplasms; Humans; Male; Metabolic Clearance Rate; Middle Aged; Pyrimidines; Reference Values; Standard of Care; Young Adult

2019
Gene expression profiles in differentiating leukemia cells induced by methyl jasmonate are similar to those of cytokinins and methyl jasmonate analogs induce the differentiation of human leukemia cells in primary culture.
    Leukemia, 2009, Volume: 23, Issue:4

    Topics: Acetates; Cell Differentiation; Cyclopentanes; Cytokinins; Esters; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Hematologic Neoplasms; HL-60 Cells; Humans; Isopentenyladenosine; Leukemia; Oxylipins; Tumor Cells, Cultured

2009